The business concept behind Inte:Ligand is a simple one: to speed up and make the drug development process safer. Fulfilling this mission is the company’s integrated software suite, which provides solutions covering lead search, optimisation and prediction of side effects and risks. Inte:Ligand has also created software tools based on experiment data and several 3D compound databases ideal for commercial virtual screening.

Earlier this year, the company filed a patent application for the discovery and application of certain compounds that it has identified as potential leads for Alzheimer’s Disease treatments. It pinpointed these molecules using a virtual screening technology that incorporates state-of-the-art pharmacophores and a natural products database.

All in all, Inte:Ligand expertise optimises and accelerates the R&D processes at the early stages of drug development. It also reduces the drop-out rate and, in turn, the risk of failure during later phases.